Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Common Equity: 2016-2025

Historic Common Equity for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $255.1 million.

  • Organogenesis Holdings' Common Equity fell 8.41% to $255.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $255.1 million, marking a year-over-year decrease of 8.41%. This contributed to the annual value of $262.9 million for FY2024, which is 5.66% down from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' Common Equity is $255.1 million, which was up 9.38% from $233.2 million recorded in Q2 2025.
  • Organogenesis Holdings' Common Equity's 5-year high stood at $278.7 million during Q4 2023, with a 5-year trough of $157.3 million in Q1 2021.
  • Moreover, its 3-year median value for Common Equity was $263.7 million (2023), whereas its average is $264.1 million.
  • In the last 5 years, Organogenesis Holdings' Common Equity spiked by 400.48% in 2021 and then fell by 12.63% in 2025.
  • Over the past 5 years, Organogenesis Holdings' Common Equity (Quarterly) stood at $241.3 million in 2021, then increased by 10.08% to $265.7 million in 2022, then rose by 4.89% to $278.7 million in 2023, then fell by 5.66% to $262.9 million in 2024, then fell by 8.41% to $255.1 million in 2025.
  • Its Common Equity was $255.1 million in Q3 2025, compared to $233.2 million in Q2 2025 and $242.9 million in Q1 2025.